Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 162

Similar articles for PubMed (Select 23958938)

1.

FUT2 and FUT3 genotype determines CA19-9 cut-off values for detection of cholangiocarcinoma in patients with primary sclerosing cholangitis.

Wannhoff A, Hov JR, Folseraas T, Rupp C, Friedrich K, Anmarkrud JA, Weiss KH, Sauer P, Schirmacher P, Boberg KM, Stremmel W, Karlsen TH, Gotthardt DN.

J Hepatol. 2013 Dec;59(6):1278-84. doi: 10.1016/j.jhep.2013.08.005. Epub 2013 Aug 16.

PMID:
23958938
2.

CA19-9 does not predict cholangiocarcinoma in patients with primary sclerosing cholangitis undergoing liver transplantation.

Fisher A, Theise ND, Min A, Mor E, Emre S, Pearl A, Schwartz ME, Miller CM, Sheiner PA.

Liver Transpl Surg. 1995 Mar;1(2):94-8.

PMID:
9346547
3.

Inflammation but not Biliary Obstruction is Associated With Level of CA19-9 in Patients with Primary Sclerosing Cholangitis.

Wannhoff A, Rupp C, Friedrich K, Brune M, Knierim J, Flechtenmacher C, Sauer P, Stremmel W, Hov JR, Schirmacher P, Weiss KH, Gotthardt DN.

Clin Gastroenterol Hepatol. 2015 Jul 17. pii: S1542-3565(15)00972-6. doi: 10.1016/j.cgh.2015.07.014. [Epub ahead of print]

PMID:
26192140
4.

Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis.

Siqueira E, Schoen RE, Silverman W, Martin J, Rabinovitz M, Weissfeld JL, Abu-Elmaagd K, Madariaga JR, Slivka A.

Gastrointest Endosc. 2002 Jul;56(1):40-7. Erratum in: Gastrointest Endosc 2002 Oct;56(4):612. Martini John [corrected to Martin John].

PMID:
12085033
5.

Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis.

Charatcharoenwitthaya P, Enders FB, Halling KC, Lindor KD.

Hepatology. 2008 Oct;48(4):1106-17. doi: 10.1002/hep.22441.

PMID:
18785620
6.

Enhanced detection of cholangiocarcinoma with serum trypsinogen-2 in patients with severe bile duct strictures.

Lempinen M, Isoniemi H, Mäkisalo H, Nordin A, Halme L, Arola J, Höckerstedt K, Stenman UH.

J Hepatol. 2007 Nov;47(5):677-83. Epub 2007 Jun 27.

PMID:
17640760
8.

Fut2 genotype is a risk factor for dominant stenosis and biliary candida infections in primary sclerosing cholangitis.

Rupp C, Friedrich K, Folseraas T, Wannhoff A, Bode KA, Weiss KH, Schirmacher P, Sauer P, Stremmel W, Gotthardt DN.

Aliment Pharmacol Ther. 2014 Apr;39(8):873-82. doi: 10.1111/apt.12663. Epub 2014 Feb 24.

PMID:
24612312
9.

Trends in pre-liver transplant screening for cholangiocarcinoma among patients with primary sclerosing cholangitis.

Trilianos P, Selaru F, Li Z, Gurakar A.

Digestion. 2014;89(2):165-73. doi: 10.1159/000357445. Epub 2014 Feb 22.

PMID:
24577150
10.

Adjusting CA19-9 values to predict malignancy in obstructive jaundice: influence of bilirubin and C-reactive protein.

La Greca G, Sofia M, Lombardo R, Latteri S, Ricotta A, Puleo S, Russello D.

World J Gastroenterol. 2012 Aug 21;18(31):4150-5. doi: 10.3748/wjg.v18.i31.4150.

11.

Diagnosis and management of cholangiocarcinoma in primary sclerosing cholangitis.

Ahrendt SA, Pitt HA, Nakeeb A, Klein AS, Lillemoe KD, Kalloo AN, Cameron JL.

J Gastrointest Surg. 1999 Jul-Aug;3(4):357-67; discussion 367-8.

PMID:
10482687
12.
13.

A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis.

Hultcrantz R, Olsson R, Danielsson A, Järnerot G, Lööf L, Ryden BO, Wahren B, Broomé U.

J Hepatol. 1999 Apr;30(4):669-73.

PMID:
10207809
14.

Detection of serum MMP-7 and MMP-9 in cholangiocarcinoma patients: evaluation of diagnostic accuracy.

Leelawat K, Sakchinabut S, Narong S, Wannaprasert J.

BMC Gastroenterol. 2009 Apr 30;9:30. doi: 10.1186/1471-230X-9-30.

15.

Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study.

Chalasani N, Baluyut A, Ismail A, Zaman A, Sood G, Ghalib R, McCashland TM, Reddy KR, Zervos X, Anbari MA, Hoen H.

Hepatology. 2000 Jan;31(1):7-11.

PMID:
10613720
16.

Orthotopic liver transplantation for primary sclerosing cholangitis. A 12-year single center experience.

Goss JA, Shackleton CR, Farmer DG, Arnaout WS, Seu P, Markowitz JS, Martin P, Stribling RJ, Goldstein LI, Busuttil RW.

Ann Surg. 1997 May;225(5):472-81; discussion 481-3.

17.

The clinical utility and limitations of serum carbohydrate antigen (CA19-9) as a diagnostic tool for pancreatic cancer and cholangiocarcinoma.

Singh S, Tang SJ, Sreenarasimhaiah J, Lara LF, Siddiqui A.

Dig Dis Sci. 2011 Aug;56(8):2491-6. doi: 10.1007/s10620-011-1709-8. Epub 2011 Apr 23.

PMID:
21516323
18.

Is a raised CA 19-9 level diagnostic for a cholangiocarcinoma in patients with no history of sclerosing cholangitis ?

John AR, Haghighi KS, Taniere P, Esmat ME, Tan YM, Bramhall SR.

Dig Surg. 2006;23(5-6):319-24. Epub 2006 Dec 14.

PMID:
17170527
19.

CA19-9 antigen levels can distinguish between benign and malignant pancreaticobiliary disease.

Morris-Stiff G, Teli M, Jardine N, Puntis MC.

Hepatobiliary Pancreat Dis Int. 2009 Dec;8(6):620-6.

20.

The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis.

Levy C, Lymp J, Angulo P, Gores GJ, Larusso N, Lindor KD.

Dig Dis Sci. 2005 Sep;50(9):1734-40.

PMID:
16133981
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk